Abstract
Treatment of Chronic Hepatitis C: An Experience Report from a Referral Center in Northeastern Brazil
Highlights
Hepatitis C virus (HCV) infection is one of the leading causes of chronic liver disease worldwide [1]
Based on the presented scenario, this paper aims to evaluate the efficacy of direct-acting antivirals (DAA) in individuals with hepatitis C in Northeast Brazil, at the Liver Study Center (LSC) of Hospital UniversitárioOnofre Lopes (HUOL/UFRN)
Treatment decision was based on the Clinical protocol and therapeutic guidelines for hepatitis C and coinfections (PCDT), considering the availability of the drugs in Brazil provided by the Unified Health System (UHS/ SUS-BRAZIL), the hepatitis C virus (HCV) virus genotype and subtype, the presence of cirrhosis and other comorbidities and previous therapy for HCV
Summary
Hepatitis C virus (HCV) infection is one of the leading causes of chronic liver disease worldwide [1]. DAAs achieve sustained virological response (SVR) in 90-95% of treated patients, compared to 50-70% of those receiving dual pegylated interferon and ribavirin therapy. They are already available, there are few studies on DAAs efficacy in the Brazilian population. Methods: Medical records of chronic HCV patients treated with DAAs from LSC were analyzed. Those patients with a follow-up of at least 12 weeks after the end of treatment were included. Conclusion: The experience of the LSC with DAAs showed a high rate of SVR and excellent tolerability
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
